Protocol to assemble metal-phenolic framework nanoparticles based on polyphenol-mediated biomimetic mineralization for wound healing in rats

Summary: Here, we present a protocol for controllable biomimetic mineralization at the nano-scale, simulating natural ion-enriched sedimentary mineralization. We describe steps for treatment of metal-organic frameworks with polyphenol-mediated stabilized mineralized precursor solution. We then detail their use as templates to assemble metal-phenolic frameworks (MPFs) with mineralized layers. Furthermore, we demonstrate the therapeutic benefits of MPF delivery by hydrogel to the full-thickness skin defect model in rats.For complete details on the use and execution of this protocol, please refer to Zhan et al. (2022).1 : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics

Synthetic Biohybrids of Red Blood Cells and Cascaded‐Enzymes@ Metal–Organic Frameworks for Hyperuricemia Treatment

Abstract Hyperuricemia, caused by an imbalance between the rates of production and excretion of uric acid (UA), may greatly increase the mortality rates in patients with cardiovascular and cerebrovascular diseases. Herein, for fast‐acting and long‐lasting hyperuricemia treatment, armored red blood cell (RBC) biohybrids, integrated RBCs with proximal, cascaded‐enzymes of urate oxidase (UOX) and catalase (CAT) encapsulated within ZIF‐8 framework‐based nanoparticles, have been fabricated based on a super‐assembly approach. Each component is crucial for hyperuricemia treatment: 1) RBCs significantly increase the circulation time of nanoparticles; 2) ZIF‐8 nanoparticles‐based superstructure greatly enhances RBCs resistance against external stressors while preserving native RBC properties (such as oxygen carrying capability); 3) the ZIF‐8 scaffold protects the encapsulated enzymes from enzymatic degradation; 4) no physical barrier exists for urate diffusion, and thus allow fast degradation of UA in blood and neutralizes the toxic by‐product H2O2. In vivo results demonstrate that the biohybrids can effectively normalize the UA level of an acute hyperuricemia mouse model within 2 h and possess a longer elimination half‐life (49.7 ± 4.9 h). They anticipate that their simple and general method that combines functional nanomaterials with living cell carriers will be a starting point for the development of innovative drug delivery systems